ArticlemAbs2026
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedCorrection.2026
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies are bivalent molecules and are thus able to engage two antigens concurrently, a property termed avidity. The therapeutic efficacy of an antibody drug can be broadly defined as a consequence of either antigen occupancy or target cell opsonization. Therefore, depending on the intended mechanism of action, avid engagement of a therapeutic antibody may be desirable in order to attain high antigen occupancy and consequent antagonism. In some cases, such as target cell opsonization and Fc-mediated cytotoxicity, avidity may limit efficacy when antigens are occupied with fewer antibodies per cell. In this study, we utilized a mathematical model of antibody-antigen binding to identify conditions under which avidity hinders or enhances therapeutic potential. We calibrated the model with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.